Status:
TERMINATED
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
Lead Sponsor:
University of Pittsburgh
Conditions:
Carcinoma, Non Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is an experimental study of the feasibility and efficacy of CT perfusion (CTP) imaging (CT blood flow measurements) in subjects with non-small cell lung cancer.
Detailed Description
Drug/Device Information 1\) Contrast 30 cc bolus of a low osmolar, iodinated CT contrast agent, which is FDA approved and used in the clinical CT Imaging procedure. 2\) Scanner The 64 row-multidet...
Eligibility Criteria
Inclusion
- Patient with any stage non-small cell lung cancer (NSCLC) who will undergo imaging with CT of the chest with intravenous contrast as standard of care. Other imaging tests will be performed as clinically indicated.
- Patient should be receiving, or planning to receive, or have received systemic therapy (chemotherapy and/or novel agents) treatment with or without radiotherapy. Patients should not be receiving adjuvant or postoperative treatment but neoadjuvant treatment is allowed.
- Histologically or cytologically proven NSCLC.
- At least one measurable primary or other intrathoracic/supraclavicular lesion ≥ 1 cm, according to Response Evaluation Criteria in Solid Tumors (RECIST); this lesion should be either proven to be malignant by biopsy or be considered malignant based on its evolution on previous imaging studies. A scan within 3-6 months prior to registration can be used as the baseline scan.
- Age 18 years or older and ability to provide informed consent.
- Subjects must use medically appropriate contraception if sexually active; women of childbearing potential must not be pregnant or breastfeeding
- Subjects must have normal renal function to participate. Standard laboratory testing to evaluate renal function will be performed prior to administering IV contrast and will be available as standard of care. Renal impairment is defined as a glomerular filtration rate of less than 60 ml/min/1.73 m2 BSA, derived from the patients' serum creatinine concentration.
Exclusion
- Subjects of reproductive potential, who are sexually active but unwilling and/or unable to use medically appropriate contraception, or women who are pregnant or breastfeeding;
- Established allergy to iodine containing contrast media
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00905801
Start Date
June 1 2009
End Date
September 1 2014
Last Update
October 21 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology
Pittsburgh, Pennsylvania, United States, 15232
2
University of Pittsburgh Cancer Institute - Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
3
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15232